Is Mounjaro Safe During Pregnancy? GD Guide (2026)

Mounjaro (tirzepatide) has been called the most effective anti-obesity drug ever developed, producing average weight loss of 20-22% in clinical trials—nearly double the results seen with semaglutide. As prescriptions have soared, more women of reproductive age are taking Mounjaro when they become pregnant. Here's what the 2026 evidence says about safety, what you should do if you're pregnant and on Mounjaro, and why it's not a treatment for gestational diabetes.

What Is Mounjaro (Tirzepatide)?

Mounjaro is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist—the first drug in its class. Unlike semaglutide (Ozempic, Wegovy), which acts only on GLP-1 receptors, tirzepatide activates two incretin hormone pathways simultaneously. This dual action produces greater weight loss and glucose-lowering than GLP-1 drugs alone.

• Mounjaro: FDA-approved for type 2 diabetes (approved 2022)
• Zepbound: FDA-approved for chronic weight management (approved 2023)
• Both contain tirzepatide; differ only in approved indication and maximum dose
• Weekly subcutaneous injection; doses range from 2.5mg to 15mg weekly

FDA Classification and Animal Data

Tirzepatide is classified as a drug requiring special consideration in pregnancy. The FDA labeling is explicit:

• Animal studies showed fetal growth reductions and structural abnormalities at clinically relevant exposures in rats
• In rabbits, fetal growth reductions occurred at doses 13 times human clinical exposure
• The drug is believed to cross the placenta based on its molecular properties
• Human data remains insufficient to establish safety

The drug label states: "Advise females of reproductive potential to use effective contraception during treatment and for 2 months after stopping MOUNJARO, based on the half-life of the drug."

Human Pregnancy Data: What We Know in 2026

Human data on tirzepatide in pregnancy is still limited. Unlike semaglutide—which has been in clinical use since 2017 and accumulated case data—tirzepatide only received FDA approval in 2022. The pregnancy registry established by Eli Lilly is still accumulating cases.

What the currently available human data shows:

• No large-scale cohort studies specific to tirzepatide in pregnancy have been published as of early 2026
• Case reports and registry cases are accumulating but not yet sufficient for definitive conclusions
• Extrapolation from semaglutide data suggests major malformations may not be dramatically elevated, but preterm birth and neonatal complications remain concerns
• Researchers emphasize that absence of evidence is not evidence of absence—more time is needed

The "Mounjaro Baby" Risk: Unplanned Pregnancy

As with Ozempic and Wegovy, Mounjaro poses a specific risk for unplanned pregnancy in women who are not intending to conceive:

Fertility Enhancement Effect

Mounjaro's powerful metabolic effects can restore ovulation in women with PCOS or weight-related anovulation. Women who were previously unable to conceive may find themselves pregnant unexpectedly after starting tirzepatide.

Oral Contraceptive Interaction

Tirzepatide slows gastric emptying significantly. This can reduce absorption of oral contraceptive pills, potentially lowering their effectiveness. Women taking oral birth control while on tirzepatide should discuss switching to a non-oral contraceptive method (IUD, patch, injection, ring) with their healthcare provider.

What Eli Lilly Recommends

The manufacturer recommends:

• Use effective contraception during treatment AND for 2 months after stopping tirzepatide
• If using oral contraceptives, switch to non-oral contraceptives or use backup methods (e.g., condoms)
• If planning pregnancy, stop tirzepatide at least 2 months before attempting conception

Can Mounjaro Treat Gestational Diabetes?

This is a question that comes up frequently, given Mounjaro's powerful glucose-lowering effects. The answer, unambiguously, is no—for multiple reasons:

1. No approved indication: Tirzepatide has not been approved or studied for gestational diabetes treatment
2. Placental transfer: The drug likely crosses the placenta, with unknown effects on fetal glucose regulation and development
3. Appetite suppression risks: Tirzepatide's potent reduction of appetite could lead to inadequate caloric and nutritional intake during pregnancy, harming fetal development
4. Nausea and vomiting: GI side effects are already common and often severe in pregnancy; tirzepatide would exacerbate this significantly
5. Established alternatives exist: Insulin has decades of safety data in pregnancy and effectively manages GD blood sugar

If You're Pregnant and Were Taking Mounjaro

Immediate Steps

1. Contact your healthcare provider today. This is not a situation to manage on your own or to delay.
2. Expect to stop tirzepatide immediately. Your provider will almost certainly recommend discontinuation, and likely transitioning to insulin if you were using it for diabetes management.
3. Don't panic based on animal data alone. Animal reproductive toxicity studies don't always predict human outcomes. The risk exists, but it is not certain.
4. Request enhanced monitoring. Ask about additional ultrasound scanning to monitor fetal growth and development.
5. Enroll in the pregnancy registry. Ask your provider about Eli Lilly's tirzepatide pregnancy registry—your participation contributes to evidence that will protect future pregnancies.

Questions to Ask Your Provider

• How many weeks was I exposed to tirzepatide during this pregnancy?
• What monitoring do you recommend given my exposure?
• If I need medication for blood sugar or weight-related conditions during pregnancy, what are the safe alternatives?
• Should I be referred to a maternal-fetal medicine specialist?
• When can I resume tirzepatide after delivery if I choose not to breastfeed?

Safe Alternatives During Pregnancy

If you were taking tirzepatide for type 2 diabetes or weight management, here are the evidence-based alternatives your provider may recommend during pregnancy:

For Blood Sugar Management

• Insulin: Gold standard. Multiple formulations available. Does not cross the placenta. Decades of safety data.
• Metformin: Used off-label in some cases. Note: metformin does cross the placenta; see our article on metformin vs. insulin for GD in 2026.

For Weight Management

• Weight loss drugs are not recommended during pregnancy; the focus shifts to appropriate gestational weight gain
• Registered dietitian guidance for nutritional management of weight during pregnancy
• Safe physical activity appropriate to pregnancy stage

After Delivery

If you want to resume tirzepatide after delivering:

• Tirzepatide is not recommended during breastfeeding due to potential transfer to breast milk and unknown effects on infants
• If not breastfeeding, discuss timing of resumption with your provider
• The postpartum period is an important window to address the metabolic factors that increase risk of type 2 diabetes

For related information, see our article on Ozempic and Wegovy in pregnancy 2026.

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider or registered dietitian for personalized guidance.